What is the antimalarial of choice for a patient with a prolonged QT interval?

Atovaquone-Proguanil is the Antimalarial of Choice for Patients with Prolonged QT Interval

For patients with pre-existing QT prolongation or risk factors for QT prolongation, atovaquone-proguanil should be used as the first-line antimalarial agent, as it demonstrates no cardiotoxicity or QTc prolongation effects 1, 2.

Treatment Algorithm by Malaria Species

For P. falciparum (Uncomplicated)

• First choice: Atovaquone-proguanil 1
• Rationale: The 2024 European guidelines explicitly state that atovaquone-proguanil is the second-line drug for patients "in whom the use of ACTs is contraindicated (i.e. risk of QT prolongation)" 1
• Evidence: Electrocardiographic studies in 42 patients showed no statistically significant change in QTc interval at baseline or after any dose of atovaquone-proguanil, either alone or combined with artesunate 2

For P. vivax, P. ovale, P. malariae, or P. knowlesi

• First choice: Atovaquone-proguanil 1
• Avoid: Chloroquine (standard first-line) due to QT prolongation risk 3
• Note: For P. vivax/P. ovale, you still need anti-relapse therapy with primaquine after G6PD testing, as atovaquone-proguanil only treats blood stages 1

For Severe/Complicated Malaria

• First choice: Artesunate IV (2.4 mg/kg at 0,12, 24h then daily) 1
• Avoid: Quinine, which causes QT prolongation and is only second-line 1
• Rationale: While artemisinin derivatives can cause post-artesunate delayed hemolysis, they do not alter ventricular repolarization 4

Drugs to Absolutely Avoid

Contraindicated antimalarials in prolonged QT:

• Quinine: Causes significant QT prolongation 1, 4
• Chloroquine: Prolongs QTc by mean 21.9 ms 3
• Halofantrine: Most cardiotoxic, significantly increases QT dispersion 4, 5
• Piperaquine-containing ACTs (DHA-PPQ): Prolongs QTc by mean 19.2 ms, with maximum predicted effect of +19.2 ms 6, 3
• Mefloquine: Though less than others, still affects cardiac repolarization 4

Critical Risk Factors to Assess

Before prescribing any antimalarial, evaluate:

• Concurrent QT-prolonging medications (increases risk 2.89-fold) 7
• Diabetes mellitus (increases risk 9.55-fold for significant QTc prolongation) 7
• Baseline QTc >450 ms in men or >470 ms in women
• Electrolyte abnormalities: hypokalemia, hypomagnesemia, hypocalcemia
• Cardiac conduction disorders or structural heart disease 3
• Age ≥12 years (higher risk of bradycardia with some agents) 3

Monitoring Recommendations

For patients requiring antimalarials other than atovaquone-proguanil:

• Obtain baseline ECG before treatment
• Repeat ECG 1 hour after each dose during treatment 2
• Monitor for QTc >500 ms or increase >60 ms from baseline
• Check and correct electrolytes before initiating therapy

Common Pitfalls

1. Assuming all artemisinin combinations are safe: While artemether-lumefantrine causes minimal QTc prolongation (+5.6 ms), dihydroartemisinin-piperaquine significantly prolongs QTc (+19.2 ms) due to the piperaquine component 3

2. Overlooking drug interactions: The number of concurrent QT-prolonging drugs directly predicts QTc response in multivariable models 7

3. Ignoring diabetes as a risk factor: Diabetic patients have nearly 10-fold increased odds of significant QTc prolongation with antimalarials 7